title: [Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology].
abstract: The capacity of solid tumours to invade the surrounding tissue and to metastasize, is correlated with the formation and degradation of structural elements in the vicinity of the tumour cells. Substances with both procoagulant activity and fibrinolytic activity are important factors in the formation or degradation of a "fibrin-fibronectin-gel matrix". This gel is subsequently transformed into the extracellular matrix, which, together with cells, will form the tumour stroma. When analyzing tumour stroma degradation products, it is obvious that the protease plasmin catalyses the disintegration of fibrin and fibronectin. Additional compounds of the tumour stroma and of the basal membrane are also, at least in part, broken down by plasmin or other proteases, such as collagenase IV and cathepsin D. The plasminogen activator urokinase (uPA) seems to play a central role as it was shown that elevated content of uPA is correlated with a high risk of early relapse and shorter overall survival, at least in breast cancer. It has been shown, that by means of quantifying uPA, patients with a relative high or low risk can even be selected within the classical risk groups, which so far are defined by the locoregional extension of the tumour and the hormone receptor status only. Evidently, as uPA content in human breast cancer tissue is an independent prognostic factor, one may speculate, that those experimental or in vitro data, which correlated increase in uPA-synthesis with malignancy, may be of direct relevance for human tumour biology. Moreover, due to these recent observations on the prognostic significance of tumour-associated proteases, new aspects for the selection of risk collectives within the node-negative breast cancer patients for adjuvant therapy have to be considered. It may well be possible, that one may affect tumour invasion and metastasis by inhibiting protease action of solid tumours by disturbing the binding of proteases to tumour cell surface receptors. As it is only a quantitative aspect, which separates benign physiological processes from tumour cell pathophysiology, experimental evidence suggests, that less drastic forms of palliative therapy can be proposed.
authors.affiliation: Frauenklinik, Technischen Universität München.
authors.forename: H
authors.initials: H
authors.lastname: Graeff
authors.forename: F
authors.initials: F
authors.lastname: Jänicke
authors.forename: M
authors.initials: M
authors.lastname: Schmitt
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D010450:Endopeptidases / Q000032:analysis*; D005109:Extracellular Matrix / Q000473:pathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000473:pathology*; D005836:Genitalia, Female / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D010450:Endopeptidases
vernacular_title: Klinische und prognostiche Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie.